R&G PharmaStudies Co. Ltd. A Total Assets
R&G PharmaStudies Co. Ltd. A total assets. Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) holds total assets worth CN¥2.40 Billion CNY (≈ $351.41 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see R&G PharmaStudies Co. Ltd. A (301333) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of R&G PharmaStudies Co. Ltd. A (2019–2025)
Total assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart illustrates how R&G PharmaStudies Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See today's stock price for R&G PharmaStudies Co. Ltd. A for real-time trading data and today's change.
R&G PharmaStudies Co. Ltd. A - Asset Composition Analysis
R&G PharmaStudies Co. Ltd. A Total Assets Breakdown (December 2025)
R&G PharmaStudies Co. Ltd. A total assets breakdown as of December 2025. R&G PharmaStudies Co. Ltd. A's total assets of CN¥2.40 Billion consist of 89.8% current assets and 10.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 47.0% |
| Accounts Receivable | CN¥133.47 Million | 5.6% |
| Inventory | CN¥59.02 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥16.25 Million | 0.7% |
| Goodwill | CN¥85.60 Million | 3.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is R&G PharmaStudies Co. Ltd. A's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: R&G PharmaStudies Co. Ltd. A's current assets represent 89.8% of total assets in 2025, an increase from 89.7% in 2019.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2025, down from 61.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
R&G PharmaStudies Co. Ltd. A Competitors by Total Assets
Key competitors of R&G PharmaStudies Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
R&G PharmaStudies Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.01 | 5.87 | 2.44 |
| Quick Ratio | 5.86 | 5.67 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.80 Billion | CN¥1.73 Billion | CN¥351.81 Million |
R&G PharmaStudies Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between R&G PharmaStudies Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | CN¥2.40 Billion |
| Market Capitalization | $816.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values R&G PharmaStudies Co. Ltd. A's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: R&G PharmaStudies Co. Ltd. A's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual total assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.40 Billion ≈ $351.14 Million |
+2.71% |
| 2024-12-31 | CN¥2.34 Billion ≈ $341.86 Million |
+12.65% |
| 2023-12-31 | CN¥2.07 Billion ≈ $303.46 Million |
+10.13% |
| 2022-12-31 | CN¥1.88 Billion ≈ $275.55 Million |
+177.96% |
| 2021-12-31 | CN¥677.47 Million ≈ $99.14 Million |
+26.31% |
| 2020-12-31 | CN¥536.36 Million ≈ $78.49 Million |
+20.03% |
| 2019-12-31 | CN¥446.86 Million ≈ $65.39 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more